429 results
8-K
EX-99.1
EYPT
EyePoint Pharmaceuticals Inc
8 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:02pm
be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
EyePoint intends to use the net
8-K
EX-99.1
72n0xqpn8tq 2v3rn
7 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
6:11pm
8-K
EX-1.1
g7i kzvogoylwv2tfy4q
7 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
6:11pm
424B5
0moi2j7c6tbf2co9ol
7 Dec 23
Prospectus supplement for primary offering
6:11am
424B5
x0oww76fz4k64zeu
4 Dec 23
Prospectus supplement for primary offering
5:31pm
8-K
EX-2.1
f7cus4dpwlen 5tkiol
18 May 23
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
7:06am
8-K
EX-10.1
ntx9unpmn83d2dp 8h8l
18 May 23
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
7:06am